Atara Biotherapeutics, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$20M
↓-81.5% -$89Mvs FY2024
Total Liabilities
$59M
↓-71.5% -$148Mvs FY2024
Cash
$8M
↓-66.1% -$17Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $20M | $109M |
| Current Assets | $12M | $65M |
| Cash | $8M | $25M |
| ST Investments | $0 | $17M |
| Receivables | $1M | $1M |
| Inventory | $0 | $11M |
| Other Current | $2M | $10M |
| Non-Current Assets | $8M | $44M |
| PPE | $73K | $1M |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $8M | $43M |
| Total Liab+Eq | $20M | $109M |
| Current Liab. | $15M | $135M |
| Accounts Payable | $127K | $4M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $15M | $130M |
| Non-Current Liab. | $44M | $72M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $44M | $72M |
| Equity | $-39M | $-97M |
| Retained Earnings | $2.02B | $2.05B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · ATRA · Comparing FY2025 vs FY2024